UPDATE 1-Sanofi's Dupixent wins U.S. approval for bigger use
Yahoo! Finance
Sanofi on Friday won expanded U.S. approval for its best-selling Dupixent injection to treat an allergic inflammation of the esophagus, the Food and Drug Administration said. There are more than 160,000 patients in the United States living with eosinophilic esophagitis, according to Sanofi. The chronic condition typically requires repeated treatments such as corticosterioids and diet change to ease the symptoms and Dupixent is the first treatment that targets the underlying cause.
Continue Reading